Ractigen Therapeutics
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2016-09-02
- Employees
- 51
- Market Cap
- -
- Website
- https://www.ractigen.com
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Ractigen Therapeutics.
- Target Recruit Count
- 32
- Registration Number
- NCT06556394
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, China
🇨🇳West China Hospital of Sichuan University, Chengdu, China
🇨🇳The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ractigen Therapeutics.
- Target Recruit Count
- 15
- Registration Number
- NCT06351904
- Locations
- 🇦🇺
GenesisCare North Shore, St Leonards, New South Wales, Australia
🇦🇺The Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺Peninsula & South Eastern Haematology and Oncology Group, Melbourne, Victoria, Australia
News
Ractigen Therapeutics Doses First Patient in Phase I Trial of RAG-17 for SOD1-Related ALS
Ractigen Therapeutics has dosed the first patient in a Phase I clinical trial of RAG-17, a siRNA therapy for ALS patients with SOD1 mutations.
Ractigen's RAG-21 Receives FDA Orphan Drug Designation for FUS-ALS Treatment
Ractigen Therapeutics' RAG-21, a novel siRNA therapy targeting the FUS gene, has received FDA Orphan Drug Designation for amyotrophic lateral sclerosis (ALS).
FDA Grants Orphan Drug Designation to Ractigen's RAG-21 for FUS-ALS
The FDA has granted Orphan Drug Designation to Ractigen Therapeutics' RAG-21 for amyotrophic lateral sclerosis (ALS) treatment, specifically targeting the FUS subtype.
Ractigen's RAG-18 Receives FDA Orphan Drug Designation for Duchenne and Becker Muscular Dystrophy
• Ractigen Therapeutics' RAG-18, a small activating RNA (saRNA) therapy, has been granted Orphan Drug Designation by the FDA for treating Duchenne and Becker muscular dystrophy. • RAG-18 previously received Rare Pediatric Disease Designation, making it the first saRNA therapy to achieve both designations, highlighting its potential for treating rare genetic conditions. • The therapy aims to increase utrophin production by targeting the UTRN gene, offering a functional substitute for the deficient dystrophin protein in DMD and BMD patients. • Preclinical data presented at OTS 2023 demonstrated RAG-18's ability to induce utrophin expression and ameliorate muscle damage in a mouse model of DMD.